CTLA4 and glomerulonephritis: CTLA4 targeted therapy was found to result in the development of interstitial pneumonia, glomerulonephritis, renal vasculitis, sialadenitis and rarely cases of hepatitis, colitis, gastritis, and arthritis with varying severity in each group (Fig. 3 E – F).